CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC

被引：10

作者：

Antonia, Scott J. ^{[1
]}

Gettinger, Scott N. ^{[2
]}

Goldman, Jonathan ^{[3
]}

Brahmer, Julie ^{[4
]}

Borghaei, Hossein ^{[5
]}

Chow, Laura Q. ^{[6
]}

Ready, Neal E. ^{[7
]}

Gerber, David E. ^{[8
]}

Juergens, Rosalyn ^{[9
]}

Shepherd, Frances ^{[10
]}

Laurie, Scott A. ^{[11
]}

Young, Tina ^{[12
]}

Geese, William J. ^{[12
]}

Agrawal, Shruti ^{[12
]}

Li, Xuemei ^{[12
]}

Hellmann, Matthew D. ^{[13
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Yale Comprehens Canc Ctr, New Haven, CT USA

[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA

[4] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[5] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[6] Univ Washington, Seattle, WA 98195 USA

[7] Duke Univ, Med Ctr, Durham, NC USA

[8] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[9] McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada

[10] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada

[11] Univ Ottawa, Ctr Canc, Ottawa Hosp, Ottawa, ON, Canada

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

关键词：

D O I：

10.1016/j.jtho.2016.09.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ORAL01.03

引用

页码：S250 / S251

页数：3